Top Story

Clinical setbacks integral to long-term success in HCV treatment

December 19, 2014

In a new report, the Pharmaceutical Research and Manufacturers of America examined the successes and failures of hepatitis C virus infection research and therapies since the infection was discovered 25 years ago.

“Hepatitis C research successes have built over time,” the report said. “Following the identification of the virus in 1989, stepwise improvements in interferon-based therapy ensued over the next two decades…After years of research and many setbacks, the first of these medicines — direct-acting antivirals — were approved in 2011. Since that time, many more of these medicines have been approved and researchers are finding even greater success in employing a combination of antiviral therapies to more effectively combat the disease.”

Veena L. Venkat, MD

Eight developments in pediatric GI conditions

December 19, 2014
Recent study data on pediatric gastrointestinal conditions have been abundant, particularly among presentations at the many gastroenterological society meetings this…
In the Journals

Cryptosporidiosis outbreak linked to calves involved in rollover accident

December 19, 2014
An outbreak of six cases of cryptosporidiosis was identified among emergency responders to a rollover accident involving a tractor-trailer carrying approximately 350…

CDC, FDA: Multistate listeriosis outbreak linked to caramel apples

December 19, 2014
The CDC and FDA announced an ongoing investigation of an outbreak of listeria infections associated with commercially produced, prepackaged caramel apples.As of Dec. 18…

Patients with complicated intra-abdominal infections achieved clinical response with eravacycline

December 19, 2014
Positive preliminary results from the phase 3 IGNITE 1 trial indicate that eravacycline is non-inferior to ertapenem in achieving clinical response in patients with…
More News Headlines »
CME
HCV Consults: Volume 1, Number 3

HCV Consults: Volume 1, Number 3

This activity is supported by educational grants from AbbVie and Genentech, Inc.

More »
Meeting News Coverage Video
thumbnail for video 3934207334001

Earlier repositioning of biologic therapies would improve outcomes in IBD

December 10, 2014
ORLANDO, Fla. — Stephen B. Hanauer, MD, FACG, AGAF, medical director of the Digestive Diseases Section at the…
More »
CME
Changing Perspectives on HCV: What Gastroenterologists Need to Know

Changing Perspectives on HCV: What Gastroenterologists Need to Know

This activity is supported by an independent educational grant from AbbVie.

Chronic hepatitis C virus (HCV) infection is a leading cause of cirrhosis, end-stage liver disease, liver transplant…
More »